Please Wait
Applying Filters...
menu
    • menu
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    An Enquiry

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Dapansutrile

    DEVELOPMENTS

    DIGITAL CONTENT

    MARKET PLACE

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    First Parkinson's Patients Enrolled In Phase 2 Trial
    First Parkinson's Patients Enrolled In Phase 2 Trial

    24 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/first-parkinsons-patients-treated-in-landmark-phase-2-trial-of-dapansutrile--expanding-a-leading-oral-nlrp3-inhibitor-into-neurological-diseases-302723428.html

    PR NEWSWIRE
    24 Mar 2026
    Share Share
    Olatec Therapeutics Shows Disease-Modifying Potential
    Olatec Therapeutics Shows Disease-Modifying Potential

    20 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/olatec-therapeutics-presented-preclinical-evidence-of-disease-modifying-activity-with-dapansutrile-in-its-parkinsons-studies-302665774.html

    PR NEWSWIRE
    20 Jan 2026
    Share Share
    Olatec to Conduct a Phase 2 Trial with its NLRP3 Inhibitor, Dapansutrile
    Olatec to Conduct a Phase 2 Trial with its NLRP3 Inhibitor, Dapansutrile

    20 Feb 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240220762945/en

    BUSINESSWIRE
    20 Feb 2024
    Share Share
    Olatec Announces High-Impact Coverage of Dapansutrile
    Olatec Announces High-Impact Coverage of Dapansutrile

    15 Feb 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220215005998/en

    BUSINESSWIRE
    15 Feb 2022
    Share Share
    Olatec Therapeutics’ Dapansutrile, a Selective NLRP3 Inhibitor
    Olatec Therapeutics’ Dapansutrile, a Selective NLRP3 Inhibitor

    29 Dec 2020

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20201229005039/en/Olatec-Therapeutics%E2%80%99-Lead-Compound-Dapansutrile-a-Selective-NLRP3-Inhibitor-Prevents-the-Inflammatory-Response-and-Restores-Cognitive-and-Behavioral-Deficits-in-a-Mouse-Model-of-Alzheimer%E2%80%99s-Disease

    BUSINESSWIRE
    29 Dec 2020
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.